Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Mounjaro proves more heart protective than Trulicity in trial of Eli Lilly diabetes drugs
06:50am, Thursday, 31'st Jul 2025
Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling medication for the disease, in reducing the risk of heart attack and stroke in a lar
Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
06:45am, Thursday, 31'st Jul 2025
Eli Lilly said its blockbuster diabetes drug Mounjaro showed similar heart health benefits as the company's older diabetes treatment, Trulicity, in a late-stage trial directly comparing the two medici
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
08:01am, Wednesday, 30'th Jul 2025
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the valu
Eli Lilly (LLY) Declines More Than Market: Some Information for Investors
06:46pm, Tuesday, 29'th Jul 2025
Eli Lilly (LLY) reached $762.95 at the closing of the latest trading day, reflecting a -5.59% change compared to its last close.
Why Eli Lilly Stock Was Looking Sickly Today
06:06pm, Tuesday, 29'th Jul 2025
One of the more popular stocks in the pharmaceutical sector of late got the cold shoulder from investors on Tuesday. Eli Lilly (LLY -5.50%) closed today's trading session down by almost 6% in value, w
Lilly set for strong quarter after Novo profit warning
03:49pm, Tuesday, 29'th Jul 2025
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook a
REDWOOD CITY, Calif. & SHENZHEN, China--(BUSINESS WIRE)--LTZ's research collaboration with Lilly advances development of its novel Myeloid Engager Platform, addressing diseases with high unmet need.
Lilly's cancer drug more effective than AbbVie's in head-to-head study
07:05am, Tuesday, 29'th Jul 2025
Eli Lilly said on Tuesday its drug, Jaypirca, was more effective in a head-to-head study against AbbVie's Imbruvica when tested in patients with a type of blood cancer.
Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05 Progression-free survival data was immature, but trending
The Big 3: OKTA, LLY, ADSK
12:01pm, Friday, 25'th Jul 2025
@ProsperTradingAcademy's Charles Moon turns to three names he sees making notable recoveries in their stock price. He talks about the "great upside" Okta Inc. (OKTA) holds, Eli Lilly's (LLY) "technica
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Friday, 25'th Jul 2025
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
EU regulator backs Eli Lilly's Alzheimer's drug after initial rejection
09:41am, Friday, 25'th Jul 2025
Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain patients with early Alzheimer's disease, reversing an initial decision from f
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
08:49am, Friday, 25'th Jul 2025
INDIANAPOLIS , July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Bost
The opinion will now be referred to the European Commission for final regulatory decision on donanemab INDIANAPOLIS , July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today
BRISBANE, Calif.--(BUSINESS WIRE)--Insert updated third paragraph, first sentence of release: Under the terms of the agreement, Gate will receive an upfront payment and equity investment and will be e
